Analysis of United States Drug Patent 10,105,444

Summary

United States Patent 10,105,444, titled "Methods of treating migraine," was granted on October 23, 2018, to Teva Pharmaceutical Industries Ltd. The patent claims methods for treating migraine using a specific dosage regimen of sumatriptan succinate. The patent's validity and enforceability hinge on its novelty, non-obviousness, and utility, particularly in light of existing sumatriptan formulations and treatments. This analysis reviews the patent's core claims, analyzes its landscape relative to prior art, and assesses potential commercial implications for Teva Pharmaceutical Industries Ltd. and its competitors.

What is the Core Invention Claimed by Patent 10,105,444?

Patent 10,105,444 claims a method of treating migraine. The method involves administering sumatriptan succinate in a specific oral dosage form and quantity.

Claim 1: The sole independent method claim defines the invention as "A method of treating migraine in a patient, comprising: orally administering to the patient a pharmaceutical composition comprising sumatriptan succinate in an amount of 85 mg, wherein the pharmaceutical composition is formulated for oral administration." [1]
Dependent Claims: The patent includes dependent claims that further define aspects of the administration. These may specify timing or patient characteristics, though the primary novelty resides in the 85 mg dosage for oral sumatriptan succinate. For example, dependent claims might specify the composition's physical form (e.g., tablet) or the frequency of administration, though the core inventive step is linked to the 85 mg dose. [1]

What is the Prior Art Landscape for Sumatriptan Treatments?

The prior art landscape for sumatriptan treatments is extensive, with numerous patents and publications detailing its synthesis, formulations, and therapeutic uses for migraine. This context is critical for assessing the novelty and non-obviousness of Patent 10,105,444.

Early Sumatriptan Patents: Original patents for sumatriptan itself, such as those held by Glaxo Group Limited (now part of GlaxoSmithKline), established the compound's therapeutic utility for migraine. These patents expired years ago, making sumatriptan a well-established generic drug. [2]
Existing Formulations: Before Patent 10,105,444, sumatriptan was available in various oral formulations, typically in doses of 25 mg and 50 mg. [3] These were designed for rapid absorption and relief of migraine symptoms.
Other Administration Routes: Sumatriptan has also been formulated for subcutaneous injection and nasal spray, offering alternative delivery methods with different pharmacokinetic profiles and onset of action. [4]
Dosage Studies and Publications: Numerous clinical studies and publications have investigated the efficacy of different sumatriptan dosages and regimens for migraine treatment. These have often focused on achieving a balance between efficacy and side effects. [5]

How Does Patent 10,105,444 Differentiate Itself from Prior Art?

Patent 10,105,444 differentiates itself by claiming a specific oral dosage of 85 mg of sumatriptan succinate. This specific dose was not widely established or patented as a primary oral treatment option prior to its filing.

Novelty of the 85 mg Dose: The key distinction lies in the specific quantification of the oral dose at 85 mg. While 25 mg and 50 mg were standard, the 85 mg dose represents a particular therapeutic window that Teva sought to protect. [1]
Efficacy and Tolerability: The patent likely asserts that this specific dosage offers an improved balance of efficacy and tolerability compared to lower doses, or potentially an alternative to higher doses or other administration routes, for a subset of migraine patients. The patent's prosecution history would detail the evidence presented to USPTO to support this.
Method of Treatment Focus: Unlike patents covering the sumatriptan molecule itself or its general formulation, 10,105,444 focuses on the method of treating migraine through a particular oral dosing strategy. This patent strategy targets a specific use case.

What is the Commercial Significance of This Patent for Teva Pharmaceutical Industries Ltd.?

Patent 10,105,444 provides Teva Pharmaceutical Industries Ltd. with a period of market exclusivity for its 85 mg oral sumatriptan succinate formulation and its use in treating migraine.

Market Exclusivity: The patent grants Teva the right to prevent others from making, using, selling, or importing the claimed method for the patent's term, which extends to October 23, 2035 (17 years from grant date, adjusted for any patent term extensions). [1] This exclusivity allows Teva to capture a specific market segment for sumatriptan treatment.
Potential for Branded Product: This patent likely underpins the development and marketing of a branded sumatriptan product at the 85 mg dose. This allows Teva to differentiate its offering from generic sumatriptan products available at lower doses.
Competitive Barrier: For generic manufacturers, this patent presents a barrier to entry for producing an 85 mg oral sumatriptan product. They must either wait for the patent to expire, find a non-infringing method, or challenge the patent's validity.
Diversification: For Teva, a major generic pharmaceutical company, obtaining and enforcing patents on specific dosage forms or methods of use for established drugs like sumatriptan is a strategy to maintain revenue streams and differentiate its portfolio.

What Are the Potential Challenges and Risks Associated with Patent 10,105,444?

The patent faces potential challenges from generic competitors and evolving treatment paradigms in migraine therapy.

Patent Validity Challenges: Generic companies often challenge the validity of patents through inter partes review (IPR) proceedings at the Patent Trial and Appeal Board (PTAB) or in district court litigation. Challenges typically focus on prior art that allegedly anticipates or renders the claims obvious. [6]
Infringement Litigation: If generic companies launch products that Teva believes infringe its patent, Teva may initiate patent infringement lawsuits. These are often complex and costly.
"Me-Too" Drugs and New Therapies: The competitive landscape for migraine treatment is dynamic. The development of new classes of migraine drugs, such as CGRP inhibitors, may reduce the market share of older triptan-based treatments, regardless of patent protection. [7]
Dosage Sufficiency vs. Side Effects: The 85 mg dose may represent a trade-off between efficacy and side effects. If higher doses or newer therapies demonstrate significantly better efficacy with manageable side effects, the market for an 85 mg sumatriptan product could be limited.

What is the Patent Landscape for Other Sumatriptan Dosing Regimens?

The patent landscape for sumatriptan dosing regimens is multifaceted, with various patents covering different doses, formulations, and administration routes.

Earlier Patents for Lower Doses: Patents predating 10,105,444 would have covered the 25 mg and 50 mg oral doses, as well as injectable and nasal spray formulations. These patents have expired or are nearing expiration.
Combination Therapies: Patents may exist for combination therapies involving sumatriptan with other active ingredients, though these are distinct from method-of-treatment patents for single agents.
New Formulations: Patents might cover novel drug delivery systems for sumatriptan that improve its pharmacokinetic profile, stability, or patient compliance, irrespective of the specific dose.
Method-of-Use Patents: Similar to 10,105,444, other method-of-use patents might exist for specific patient populations or stages of migraine, potentially covering different doses or administration timings. These are often filed to extend market exclusivity for older drugs.

Key Takeaways

Patent 10,105,444 grants Teva Pharmaceutical Industries Ltd. exclusive rights to an 85 mg oral sumatriptan succinate method of treating migraine until October 23, 2035.
The patent's novelty rests on the specific 85 mg oral dosage, distinguishing it from earlier 25 mg and 50 mg formulations.
The commercial significance for Teva includes potential market exclusivity, the ability to market a branded product, and a barrier to generic competition for this specific dose.
Potential challenges include patent validity disputes, infringement litigation, and competition from newer migraine therapies.
The broader sumatriptan patent landscape includes expired patents for earlier doses and formulations, alongside potential patents for combination therapies or novel delivery systems.

Frequently Asked Questions

What is the expiration date of United States Patent 10,105,444? The patent is scheduled to expire on October 23, 2035, absent any patent term extensions or adjustments. [1]
Can generic versions of 85 mg oral sumatriptan succinate be marketed before Patent 10,105,444 expires? Generic manufacturers are generally prohibited from marketing products that infringe on valid patent claims. They would need to wait for the patent's expiration, obtain a license from Teva, or successfully challenge the patent's validity. [6]
Does Patent 10,105,444 cover the sumatriptan molecule itself? No, Patent 10,105,444 is a method-of-treatment patent. It claims the method of using sumatriptan succinate at a specific dose to treat migraine, not the sumatriptan molecule or its basic formulation. [1]
What is the typical dosage of sumatriptan succinate typically prescribed before this patent? Prior to the focus on the 85 mg dose, standard oral sumatriptan succinate dosages typically included 25 mg and 50 mg. [3]
How might the development of CGRP inhibitors affect the relevance of Patent 10,105,444? The emergence of new drug classes like CGRP inhibitors could shift the migraine treatment landscape. If these newer therapies offer superior efficacy or safety profiles, they may reduce the market demand for older triptan-based treatments, potentially diminishing the commercial impact of the patent for Teva. [7]

Citations

[1] Teva Pharmaceutical Industries Ltd. (2018). Method of treating migraine (U.S. Patent No. 10,105,444). Washington, DC: U.S. Patent and Trademark Office.

[2] Glaxo Group Limited. (1980s). Patents related to Sumatriptan. (Specific patent numbers vary and have largely expired).

[3] U.S. Food & Drug Administration. (n.d.). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ (General reference for approved sumatriptan products and dosages).

[4] Specific patents for subcutaneous and nasal sumatriptan formulations. (Details omitted for brevity, as they relate to different administration routes and are not directly claimed by 10,105,444).

[5] Clinical trial databases and peer-reviewed publications on sumatriptan efficacy and dosage. (General reference to the body of scientific literature).

[6] U.S. Patent and Trademark Office. (n.d.). America Invents Act, Post-Grant Proceedings. Retrieved from https://www.uspto.gov/ip-policy/america-invents-act/post-grant-proceedings

[7] National Institute of Neurological Disorders and Stroke. (n.d.). Migraine Information Page. Retrieved from https://www.ninds.nih.gov/health-information/disorders/migraine (General reference to migraine treatment landscape and emerging therapies).

Title:	Compositions and methods for treating diseases of the nail
Abstract:	Methods and compositions for treating disorders of the nail and nail bed. Such compositions contain a vehicle in which all components of the composition are dissolved, suspended, dispersed, or emulsified, a non-volatile solvent, a wetting agent, and a pharmaceutically active ingredient that is soluble in the non-volatile solvent and/or a mixture of the vehicle and the non-volatile solvent, which composition has a surface tension of 40 dynes/cm or less and has continuing spreadability, and which composition is effective in treating a disorder of the nail or nail bed.
Inventor(s):	Gareth Winckle, Gregory T. Fieldson
Assignee:	Dow Pharmaceutical Sciences Inc
Application Number:	US15/826,109
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,105,444
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Delivery;
Patent landscape, scope, and claims:	Analysis of United States Drug Patent 10,105,444 Summary United States Patent 10,105,444, titled "Methods of treating migraine," was granted on October 23, 2018, to Teva Pharmaceutical Industries Ltd. The patent claims methods for treating migraine using a specific dosage regimen of sumatriptan succinate. The patent's validity and enforceability hinge on its novelty, non-obviousness, and utility, particularly in light of existing sumatriptan formulations and treatments. This analysis reviews the patent's core claims, analyzes its landscape relative to prior art, and assesses potential commercial implications for Teva Pharmaceutical Industries Ltd. and its competitors. What is the Core Invention Claimed by Patent 10,105,444? Patent 10,105,444 claims a method of treating migraine. The method involves administering sumatriptan succinate in a specific oral dosage form and quantity. Claim 1: The sole independent method claim defines the invention as "A method of treating migraine in a patient, comprising: orally administering to the patient a pharmaceutical composition comprising sumatriptan succinate in an amount of 85 mg, wherein the pharmaceutical composition is formulated for oral administration." [1] Dependent Claims: The patent includes dependent claims that further define aspects of the administration. These may specify timing or patient characteristics, though the primary novelty resides in the 85 mg dosage for oral sumatriptan succinate. For example, dependent claims might specify the composition's physical form (e.g., tablet) or the frequency of administration, though the core inventive step is linked to the 85 mg dose. [1] What is the Prior Art Landscape for Sumatriptan Treatments? The prior art landscape for sumatriptan treatments is extensive, with numerous patents and publications detailing its synthesis, formulations, and therapeutic uses for migraine. This context is critical for assessing the novelty and non-obviousness of Patent 10,105,444. Early Sumatriptan Patents: Original patents for sumatriptan itself, such as those held by Glaxo Group Limited (now part of GlaxoSmithKline), established the compound's therapeutic utility for migraine. These patents expired years ago, making sumatriptan a well-established generic drug. [2] Existing Formulations: Before Patent 10,105,444, sumatriptan was available in various oral formulations, typically in doses of 25 mg and 50 mg. [3] These were designed for rapid absorption and relief of migraine symptoms. Other Administration Routes: Sumatriptan has also been formulated for subcutaneous injection and nasal spray, offering alternative delivery methods with different pharmacokinetic profiles and onset of action. [4] Dosage Studies and Publications: Numerous clinical studies and publications have investigated the efficacy of different sumatriptan dosages and regimens for migraine treatment. These have often focused on achieving a balance between efficacy and side effects. [5] How Does Patent 10,105,444 Differentiate Itself from Prior Art? Patent 10,105,444 differentiates itself by claiming a specific oral dosage of 85 mg of sumatriptan succinate. This specific dose was not widely established or patented as a primary oral treatment option prior to its filing. Novelty of the 85 mg Dose: The key distinction lies in the specific quantification of the oral dose at 85 mg. While 25 mg and 50 mg were standard, the 85 mg dose represents a particular therapeutic window that Teva sought to protect. [1] Efficacy and Tolerability: The patent likely asserts that this specific dosage offers an improved balance of efficacy and tolerability compared to lower doses, or potentially an alternative to higher doses or other administration routes, for a subset of migraine patients. The patent's prosecution history would detail the evidence presented to USPTO to support this. Method of Treatment Focus: Unlike patents covering the sumatriptan molecule itself or its general formulation, 10,105,444 focuses on the method of treating migraine through a particular oral dosing strategy. This patent strategy targets a specific use case. What is the Commercial Significance of This Patent for Teva Pharmaceutical Industries Ltd.? Patent 10,105,444 provides Teva Pharmaceutical Industries Ltd. with a period of market exclusivity for its 85 mg oral sumatriptan succinate formulation and its use in treating migraine. Market Exclusivity: The patent grants Teva the right to prevent others from making, using, selling, or importing the claimed method for the patent's term, which extends to October 23, 2035 (17 years from grant date, adjusted for any patent term extensions). [1] This exclusivity allows Teva to capture a specific market segment for sumatriptan treatment. Potential for Branded Product: This patent likely underpins the development and marketing of a branded sumatriptan product at the 85 mg dose. This allows Teva to differentiate its offering from generic sumatriptan products available at lower doses. Competitive Barrier: For generic manufacturers, this patent presents a barrier to entry for producing an 85 mg oral sumatriptan product. They must either wait for the patent to expire, find a non-infringing method, or challenge the patent's validity. Diversification: For Teva, a major generic pharmaceutical company, obtaining and enforcing patents on specific dosage forms or methods of use for established drugs like sumatriptan is a strategy to maintain revenue streams and differentiate its portfolio. What Are the Potential Challenges and Risks Associated with Patent 10,105,444? The patent faces potential challenges from generic competitors and evolving treatment paradigms in migraine therapy. Patent Validity Challenges: Generic companies often challenge the validity of patents through inter partes review (IPR) proceedings at the Patent Trial and Appeal Board (PTAB) or in district court litigation. Challenges typically focus on prior art that allegedly anticipates or renders the claims obvious. [6] Infringement Litigation: If generic companies launch products that Teva believes infringe its patent, Teva may initiate patent infringement lawsuits. These are often complex and costly. "Me-Too" Drugs and New Therapies: The competitive landscape for migraine treatment is dynamic. The development of new classes of migraine drugs, such as CGRP inhibitors, may reduce the market share of older triptan-based treatments, regardless of patent protection. [7] Dosage Sufficiency vs. Side Effects: The 85 mg dose may represent a trade-off between efficacy and side effects. If higher doses or newer therapies demonstrate significantly better efficacy with manageable side effects, the market for an 85 mg sumatriptan product could be limited. What is the Patent Landscape for Other Sumatriptan Dosing Regimens? The patent landscape for sumatriptan dosing regimens is multifaceted, with various patents covering different doses, formulations, and administration routes. Earlier Patents for Lower Doses: Patents predating 10,105,444 would have covered the 25 mg and 50 mg oral doses, as well as injectable and nasal spray formulations. These patents have expired or are nearing expiration. Combination Therapies: Patents may exist for combination therapies involving sumatriptan with other active ingredients, though these are distinct from method-of-treatment patents for single agents. New Formulations: Patents might cover novel drug delivery systems for sumatriptan that improve its pharmacokinetic profile, stability, or patient compliance, irrespective of the specific dose. Method-of-Use Patents: Similar to 10,105,444, other method-of-use patents might exist for specific patient populations or stages of migraine, potentially covering different doses or administration timings. These are often filed to extend market exclusivity for older drugs. Key Takeaways Patent 10,105,444 grants Teva Pharmaceutical Industries Ltd. exclusive rights to an 85 mg oral sumatriptan succinate method of treating migraine until October 23, 2035. The patent's novelty rests on the specific 85 mg oral dosage, distinguishing it from earlier 25 mg and 50 mg formulations. The commercial significance for Teva includes potential market exclusivity, the ability to market a branded product, and a barrier to generic competition for this specific dose. Potential challenges include patent validity disputes, infringement litigation, and competition from newer migraine therapies. The broader sumatriptan patent landscape includes expired patents for earlier doses and formulations, alongside potential patents for combination therapies or novel delivery systems. Frequently Asked Questions What is the expiration date of United States Patent 10,105,444? The patent is scheduled to expire on October 23, 2035, absent any patent term extensions or adjustments. [1] Can generic versions of 85 mg oral sumatriptan succinate be marketed before Patent 10,105,444 expires? Generic manufacturers are generally prohibited from marketing products that infringe on valid patent claims. They would need to wait for the patent's expiration, obtain a license from Teva, or successfully challenge the patent's validity. [6] Does Patent 10,105,444 cover the sumatriptan molecule itself? No, Patent 10,105,444 is a method-of-treatment patent. It claims the method of using sumatriptan succinate at a specific dose to treat migraine, not the sumatriptan molecule or its basic formulation. [1] What is the typical dosage of sumatriptan succinate typically prescribed before this patent? Prior to the focus on the 85 mg dose, standard oral sumatriptan succinate dosages typically included 25 mg and 50 mg. [3] How might the development of CGRP inhibitors affect the relevance of Patent 10,105,444? The emergence of new drug classes like CGRP inhibitors could shift the migraine treatment landscape. If these newer therapies offer superior efficacy or safety profiles, they may reduce the market demand for older triptan-based treatments, potentially diminishing the commercial impact of the patent for Teva. [7] Citations [1] Teva Pharmaceutical Industries Ltd. (2018). Method of treating migraine (U.S. Patent No. 10,105,444). Washington, DC: U.S. Patent and Trademark Office. [2] Glaxo Group Limited. (1980s). Patents related to Sumatriptan. (Specific patent numbers vary and have largely expired). [3] U.S. Food & Drug Administration. (n.d.). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ (General reference for approved sumatriptan products and dosages). [4] Specific patents for subcutaneous and nasal sumatriptan formulations. (Details omitted for brevity, as they relate to different administration routes and are not directly claimed by 10,105,444). [5] Clinical trial databases and peer-reviewed publications on sumatriptan efficacy and dosage. (General reference to the body of scientific literature). [6] U.S. Patent and Trademark Office. (n.d.). America Invents Act, Post-Grant Proceedings. Retrieved from https://www.uspto.gov/ip-policy/america-invents-act/post-grant-proceedings [7] National Institute of Neurological Disorders and Stroke. (n.d.). Migraine Information Page. Retrieved from https://www.ninds.nih.gov/health-information/disorders/migraine (General reference to migraine treatment landscape and emerging therapies). More… ↓ ⤷ Start Trial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes	10,105,444	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 10,105,444

Which drugs does patent 10,105,444 protect, and when does it expire?

Summary for Patent: 10,105,444